Former NCL Collaborator NANOBIOTIX recently announced European market approval for their formulation Hensify® (NBTXR3). Per the press release:
Nanotechnology Characterization Lab
Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.
News & Updates
NCL's Immunology team has put together a series of new protocols which probe various immunotoxicology aspects of nanomedicines.
- 1 of 4
- next ›
Meet Us @
Following the success of a 2016 NYAS meeting titled “Equivalence of Complex Drug Products: Scientific and Regulatory Challenges,” the Academy, in collaboration with the...